The Clinuvel (ASX:CUV) share price is dipping today

The Clinuvel (ASX: CUV) share price is dropping today after the company released its quarterly report. We take a closer look.
The post The Clinuvel (ASX:CUV) share price is dipping today appeared first on The Motley Fool Australia. –

falling asx share price represented by woman making sad face

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is falling despite positive news in its quarterly report released today.

At the time of writing, the Clinuvel share price is trading at $22.0, down 1.35%.

What’s driving the Clinuvel share price today?

In its quarterly report for the period ending 31 December 2020, the biopharmaceutical company highlighted negative market conditions as a result of COVID-19 impacts.

Nonetheless, Clinuvel expanded both its commercial operation in the US and its research and development program despite the challenging conditions. The company said the expansion went ahead without the use of any equity or debt financing.

And, as hospital and medical supplies face new challenges, Clinuvel was also able to strengthen its business and balance sheet. This was underpinned by record positive cash receipts, leading to increased cash reserves.

Also during the quarter, the company progressed a number of key projects, including TGA approval of the drug Scenesse to treat adult patients with erythropoietic protoporphyria.

The commercial distribution Scenesse in the United States and Europe delivered cash receipts of $5,266,000. Net cash flow from operating activities came in at $1,293,000. This takes the rolling annual cash receipts value to $33 million, the highest since the company began commercial operations in 2016.

Cash receipts where increasing expenditures from net operating activies also increased to $4,111,000. However, the company claimed this was in order to fund future growth.

Management commentary

Commenting on the update, Clinuvel chief financial officer Darren Keamy said:

The continued performance of the group stems from our measured strategy, consistent execution, and treatment demand from both the USA and Europe, which have contributed to a new high in annual cash receipts.

Against the ongoing backdrop of economic uncertainty, and in a quarter where cash receipts are historically lower reflecting the seasonal demand, we have now been able to deliver a positive net cash result in the December quarter, the first since 2017.

About the Clinuvel share price

Despite a stream of positive company announcements, the Clinuvel share price has performed poorly over the past month, dropping 6% lower. It comes as Clinuvel remains one of the most shorted shares on the ASX.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Clinuvel (ASX:CUV) share price is dipping today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!